drugset / Trial / NCT05947825
Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients
Phase 2
Enrolling by invitation
30 enrolled
Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the efficacy of sitagliptin combined with gemcitabine and albumin-bound paclitaxel in subjects with locally advanced and metastatic pancreatic ductal adenocarcinoma.
Timeline
- Start
- 2023-07-01
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Sitagliptin | Small molecule | 100 mg | Oral |